DOCSLIB.ORG

US 2007/008284.0 A1 Porter Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20070082840A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/008284.0 A1 Porter et al. (43) Pub. Date: Apr. 12, 2007 (54) COMBINATION THERAPY FOR INHIBITION Publication Classification OF PLATELET AGGREGATION (51) Int. Cl. A6II 38/12 (2006.01) (76) Inventors: R. Stephen Porter, Franklin, TN (US); A6II 38/06 (2006.01) Kristen K. Flaharty, Fort Myers, FL A6II 38/05 (2006.01) (US); James E. Tcheng. Durham, NC A 6LX 3L/727 (2006.01) (US); John W. Ferkany, Brighton, MA A61K 3 I/5513 (2006.01) (US) A61K 31/5377 (2006.01) A6II 3/445 (2006.01) (52) U.S. Cl. ............... 514/9: 514/18: 514/317; 514/221; Correspondence Address: 514/326; 514/232.5: 514/56 CLARK & ELBNG LLP (57) ABSTRACT 101 FEDERAL STREET The invention features methods for preventing platelet acti BOSTON, MA 02110 (US) Vation and aggregation and for treating individuals Suffering from conditions or undergoing procedures that may result in (21) Appl. No.: 11/515,596 unwanted platelet aggregation. The methods are based on (22) Filed: Sep. 5, 2006 the intravenous, Subcutaneous, or transdermal administra tion of a platelet activation or aggregation inhibitor, e.g., Related U.S. Application Data Xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The (63) Continuation of application No. PCT/US05/07440, treatment may commence prior to a medical or Surgical filed on Mar. 7, 2005. procedure or after the outbreak of an adverse medical condition, either of which results in the activation of plate (60) Provisional application No. 60/550,792, filed on Mar. lets that may lead to thrombus formation, and may continue 5, 2004. thereafter. Patent Application Publication Apr. 12, 2007 Sheet 1 of 2 US 2007/008284.0 A1 SM-20302 SR 90.107 L-734,217 SDZ GPI 562 RWJ-50042 TP-92.01 Figure 1 Patent Application Publication Apr. 12, 2007 Sheet 2 of 2 US 2007/008284.0 A1 ME-3277 OCHCOOH OCHCOOH UR-12947 SANORG 34006 Figure 1 (continued) US 2007/008284.0 A1 Apr. 12, 2007 COMBINATION THERAPY FOR INHIBITION OF (e.g., via a patch, Sonophoresis, a microneedle array, or PLATELET AGGREGATION iontophoresis) administering a first platelet activation or aggregation inhibitor to the Subject; and orally administering CROSS-REFERENCE TO RELATED a second platelet activation or aggregation inhibitor to the APPLICATIONS subject, provided that, when the first platelet activation or aggregation inhibitor is heparin, the second platelet activa 0001) This application is a continuation of PCT/US2005/ tion or aggregation inhibitor is not aspirin, and provided that 007.440 filed Mar. 7, 2005, which, in turn, claims benefit of when the first platelet activation or aggregation inhibitor is U.S. Provisional Patent Application Ser. No. 60/550,792, RPR 109891, the second platelet activation or aggregation filed Mar. 5, 2004; the disclosures of which are each hereby inhibitor is not RPR 109891. The first and second platelet incorporated by reference in their entirety. activation or aggregation inhibitors may be the same or different. The method may further include administering a BACKGROUND OF THE INVENTION cholesterol lowering agent, an agent that modifies eicosanoid activity, a 5HT2a antagonist, nonsteroidal anti 0002 The invention relates to the field of medical treat inflammatory drugs, an adrenergic inhibitor, an angiotensin ments, in particular the inhibition of platelet aggregation. converting enzyme inhibitor, an angiotensin II receptor 0003 Fibrinogen is a glycoprotein present as a normal antagonist, a fibrilyinic agent, a beta blocker, a calcium component of blood plasma. It participates in platelet aggre channel blocker, a diuretic agent, a steroid, a steroidal gation and fibrin formation in the blood clotting mechanism. glycoside, a nicotinic acid drug, a bile acid sequestrant, a Platelets are cellular elements found in whole blood, which fibrate, ETC 588 (liposome), ETC 216 (ApoA-I Milano/ also participate in blood coagulation. Fibrinogen binding to phospholipid complex), ETC 642 (RLT Peptide), pirozadil, platelets is important for normal platelet function in the or a vasodilator or to the Subject, e.g., with the first or second blood coagulation mechanism. When a blood vessel receives platelet aggregation inhibitor or separately. an injury, the platelets binding to fibrinogen will initiate 0007 Exemplary first or second platelet activation or aggregation and form a thrombus. Injury can occur during aggregation inhibitors include a GP IIb/IIIa antagonist, a medical or Surgical procedures. In addition, certain medical heparin, tissue plasminogen activator, a Factor Xa inhibitor, conditions, such as diabetes, leads to platelet aggregation a purinergic-receptor antagonist, a thrombin inhibitor, a and thrombosis in Vital organs. Interaction offibrinogen with phosphodiesterase inhibitor (e.g., dipyridamole), a platelets occurs through a membrane glycoprotein complex, cyclooxygenase inhibitor (e.g., aspirin), a CD40 antagonist, known as glycoprotein IIb/IIIa (GPIb/IIIa). Inhibitors of and a leukotriene inhibitor. Examples of GPIb/IIIa antago this interaction are useful in modulating or preventing nists include tirofiban, abciximab, eptifibatide, TRM-147, platelet thrombus formation. SM-20302, L-378167, rClf A, ME-3230, SR-121787, 0004 The activation of platelets and the resultant aggre UR-12947, L-734217, DMP-757, EMD-96717, SDZ-GPI gation have been shown to be important factors in the 562, RG-13965, SB-207448, SC-56929, RWJ-50042, UR pathogenesis of acute coronary syndrome, unstable angina 4005, L-703014, SKF-106760, CRL-42796, HMR-1794, pectoris, transient myocardial ischemia, acute myocardial CGH-400, Ro-43-5054, Barbourin, Bitistatin, SC-49992, infarction, peripheral arterial occlusion, and atherosclerosis. TP-9201, MA-16N7C2, roxifiban (DMP-754), lamifiban, In most of these serious cardiovascular disorders, intracoro Xemilofiban, lotrafiban, sibrafiban, DU-728, DMP-728, nary or intra-arterial thrombus is present. The thrombus is MK-852, SC-52012A, echistatin, TAK-029, ME-3277, generally formed by activated platelets that adhere and T-250, MS-180, TA-993, elarofiban (RWJ-53308), croma aggregate at the site of endothelial injury or plaque rupture. fiban (CT-50352), YM-337, lefradafiban (BIBU-104), Because of the relative contribution of activated platelets to fradafiban (BIBU-52), ZD-2486, RPR-109891, gantofiban, aggregation and Subsequent formation of an occlusive GR-144053F, and pharmaceutically acceptable salts thereof. thrombus, antiplatelet agents have been developed that Exemplary heparins include low molecular weight heparins, inhibit platelet activation or aggregation. Such as ardeparin, certoparin, dalteparin, enoxaparin, nadro parin, reviparin, SNAD-UFH, SNAC-UFH, or tinazaparin. SUMMARY OF THE INVENTION Factor Xa inhibitors include coumadin, danaparoid, fonda parinux, CL-1031, DPC 906, Sanorg-34006, MCM 16, 0005 The present invention provides methods for pre MCM 17, BAY 59-7939, KFA-1982, GH9001, DPC423, venting platelet activation and aggregation and for treating ZD4927, DX-9065a, YM 60828, SR 90107, FXV673, and individuals Suffering from conditions or undergoing proce tifacogin. The purinergic-receptor antagonist is for example dures that may result in unwanted platelet aggregation. The a P2Y or P2Y antagonist or both. P2Y antagonists methods are based on the intravenous, Subcutaneous, or include clopidogrel, cangrelor, and ticlopidine, and P2Y transdermal administration of a platelet activation or aggre antagonists include ATP and MRS 2179 (2'-deoxy-N6-me gation inhibitor, e.g., xemilofiban, followed by oral admin thyladenosine 3',5'-bisphosphate). Exemplary thrombin istration of the same or a different platelet activation or inhibitors re bivalirudin, lepirudin, argatroban, melagatran, aggregation inhibitor. The treatment may commence prior to Ximelagatran, antithrombin IIII, dermatan, mesoglycan, a medical or Surgical procedure or after the outbreak of an MB-015, H-376/95, BIBR 1048, efegatran, TRI-50B, adverse medical condition, either of which results in the inogatran, V19, and PEG-r-hirudin. CD40 antagonists activation of platelets that may lead to thrombus formation, include soluble CD40 ligand and a CD40 antibody, and and may continue thereafter. leukotriene inhibitors include monelukast, Zafirlukast, and 0006. In one aspect, the invention features a method of Zileuton. inhibiting platelet aggregation in a Subject including the 0008. When the subject has a body mass index of greater steps of intravenously, Subcutaneously, or transdermally than 30, 4 to 10 mg of the first platelet activation or US 2007/008284.0 A1 Apr. 12, 2007 aggregation inhibitor is typically administered, and when the Vation or aggregation inhibitor, e.g., xemilofiban, may be subject has a body mass index of less than 30, 1 to 3 mg of administered for at least 1 day, e.g., at least 2, 7, 14, or 30 the first platelet activation or aggregation inhibitor is typi days. cally administered. 0011. The invention further features a method of inhib 0009. The intravenous, transdermal, or subcutaneous iting platelet aggregation in a Subject including Subcutane administration may also occur prior to or during a medical ously administering a platelet aggregation, a Factor Xa or Surgical procedure, e.g., a cardiovascular interventional inhibitor, a heparin, and a thrombin inhibitor to the subject. procedure. Exemplary cardiovascular interventional proce The platelet aggregation inhibitor is, for example, a GP dures include percutaneous
Recommended publications
  • NTP42, a Novel Antagonist of the Thromboxane Receptor, Attenuates Experimentally Induced Pulmonary Arterial Hypertension Eamon P

    NTP42, a Novel Antagonist of the Thromboxane Receptor, Attenuates Experimentally Induced Pulmonary Arterial Hypertension Eamon P

    Mulvaney et al. BMC Pulmonary Medicine (2020) 20:85 https://doi.org/10.1186/s12890-020-1113-2 RESEARCH ARTICLE Open Access NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension Eamon P. Mulvaney1, Helen M. Reid1,2, Lucia Bialesova1, Annie Bouchard3, Dany Salvail3 and B. Therese Kinsella1,2* Abstract Background: NTP42 is a novel antagonist of the thromboxane prostanoid receptor (TP), currently in development for the treatment of pulmonary arterial hypertension (PAH). PAH is a devastating disease with multiple pathophysiological hallmarks including excessive pulmonary vasoconstriction, vascular remodelling, inflammation, fibrosis, in situ thrombosis and right ventricular hypertrophy. Signalling through the TP, thromboxane (TX) A2 is a potent vasoconstrictor and mediator of platelet aggregation. It is also a pro-mitogenic, pro-inflammatory and pro-fibrotic agent. Moreover, the TP also mediates the adverse actions of the isoprostane 8-iso-prostaglandin F2α, a free-radical-derived product of arachidonic acid produced in abundance during oxidative injury. Mechanistically, TP antagonists should treat most of the hallmarks of PAH, including inhibiting the excessive vasoconstriction and pulmonary artery remodelling, in situ thrombosis, inflammation and fibrosis. This study aimed to investigate the efficacy of NTP42 in the monocrotaline (MCT)-induced PAH rat model, alongside current standard-of-care drugs. Methods: PAH was induced by subcutaneous injection of 60 mg/kg MCT in male Wistar–Kyoto rats. Animals were assigned into groups: 1. ‘No MCT’;2.‘MCT Only’;3.MCT+NTP42 (0.25mg/kgBID);4.MCT+Sildenafil(50mg/kgBID),and5.MCT+ Selexipag (1 mg/kg BID), where 28-day drug treatment was initiated within 24 h post-MCT.
  • Lawout Journal.Qxd

    Lawout Journal.Qxd

    University Heart Journal Vol. 6, No. 1, January 2010 Therapeutic Options for the Treatment of Pulmonary Hypertension Rownak Jahan Tamanna 1 1Department of Cardiology, BIRDEM Address for Correspondance Dr. Rownak Jahan Tamanna, Department of Cardiology, BIRDEM , Dhaka e- mail : [email protected] Abstract The therapy of pulmonary hypertension depends on the identification of underlying contributing factors. pulmonary arterial hypertension ( PAH) , which can be idiopathic or related to connective tissue disease, portal hypertension, HIV disease, inges - tion of certain drugs or toxins, or congenital heart disease, had no specific therapy until recently. However, the past decade has seen remarkable progress, and these heretofore devastating and usually lethal forms of pulmonary hypertension now often respond to one form of therapy or another, leading to improved functional capacity and even survival. The following will consider the major pharmacotherapy’s now available for PAH and suggest a framework for therapeutic decision-making. Key word : Pulmonary hypertension Introduction although they can be quite useful for ameliorating symp - Pulmonary hypertension refers to an abnormal elevation of toms, they do not significantly affect the natural history of pulmonary artery ( PA ) pressure (mean PA pressure > 25 mm the disease. Hg at rest and 30 mm Hg with exercise). Newer and more effective pharmacotherapy’s for PAH are It is a rare disease of unknown etiology, whereas secondary now available, starting with prostacyclins in 1996 and, more pulmonary hypertension is a complication of pulmonary, recently, endothelin receptor antagonists and phosphodi - cardiac and extrathoracic conditions. Unrelieved pulmonary esterase 5 inhibitors. Relative merits of the different thera - hypertension can lead to right heart failure.
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Characterising the Risk of Major Bleeding in Patients With

    Characterising the Risk of Major Bleeding in Patients With

    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
  • In Vitro and in Vivo Pharmacological Characterization of BM-613, a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane

    In Vitro and in Vivo Pharmacological Characterization of BM-613, a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane

    JPET Fast Forward. Published on December 30, 2004 as DOI: 10.1124/jpet.104.079301 JPET FastThis Forward. article has not Published been copyedited on andDecember formatted. The 30, final 2004 version as mayDOI:10.1124/jpet.104.079301 differ from this version. JPET #79301 In vitro and in vivo pharmacological characterization of BM-613, a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist Julien Hanson*, Stephanie Rolin*, Denis Reynaud, Na Qiao, Leanne P. Kelley, Helen M. Reid, François Valentin, John Tippins, Therese B. Kinsella, Bernard Masereel, Cecil Pace- Downloaded from Asciak, Bernard Pirotte, and Jean-Michel Dogné Natural and Synthetic Drugs Research Centre, Department of Pharmacy, Laboratory of jpet.aspetjournals.org Medicinal Chemistry, University of Liège, 1, Av. de l'Hôpital, B-4000 Liège, Belgium. (J.H., J-M.D., B.P.) Department of Pharmacy, University of Namur, 61, rue de Bruxelles, B-5000 Namur, at ASPET Journals on September 24, 2021 Belgium. (S.R., B.M.) Programme in Integrative Biology, Research Institute, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. (D.R., N.Q., C.P-A.) Department of Biochemistry, Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Ireland. (L.P.K., H.M.R., T.B.K.) Department of Biological Sciences, Imperial College, Exhibition Road, London SW7 2AZ, United Kingdom. (F.V., J.T.) 1 Copyright 2004 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on December 30, 2004 as DOI: 10.1124/jpet.104.079301 This article has not been copyedited and formatted.
  • Role of Thromboxane Receptor-Alpha in Prostate Cancer Progression Prasanna Ekambaram Wayne State University

    Role of Thromboxane Receptor-Alpha in Prostate Cancer Progression Prasanna Ekambaram Wayne State University

    Wayne State University Wayne State University Dissertations 1-1-2012 Role Of Thromboxane Receptor-Alpha In Prostate Cancer Progression Prasanna Ekambaram Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Recommended Citation Ekambaram, Prasanna, "Role Of Thromboxane Receptor-Alpha In Prostate Cancer Progression" (2012). Wayne State University Dissertations. Paper 591. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. ROLE OF THROMBOXANE RECEPTOR-ALPHA IN PROSTATE CANCER PROGRESSION by PRASANNA EKAMBARAM DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2012 MAJOR: CANCER BIOLOGY Approved by: ______________________________ Advisor Date ______________________________ ______________________________ ______________________________ ______________________________ © COPYRIGHT BY PRASANNA EKAMBARAM 2012 All rights reserved DEDICATION I would like to dedicate this dissertation to my wife, Arulselvi and my kids Tejas and Abhi for standing strong by my side at good times and difficult times in life and helping me work hard toward achieving my goal of being a research scientist; To my parents for their blessings, and prayers and for helping to come to Unites States to complete my graduate studies. ii ACKNOWLEDGMENTS Foremost, I would like to extend my gratitude to my mentor, Dr. Honn for giving me this wonderful opportunity to work in his laboratory and to be my mentor for my PhD program. I would like to thank him for his immense patience, the support and guidance through the years.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and Surgical Management for Pulmonary Arterial Hypertension

    Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and Surgical Management for Pulmonary Arterial Hypertension

    Guidelines Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension Majdy M. Idrees, John Swiston1, Imran Nizami2, Abdullah Al Dalaan3, Robert D. Levy1 Pulmonary Medicine, Abstract: Prince Sultan Medical Prior to the availability of the pulmonary arterial hypertension (PAH)-specific therapy, PAH was a dreadful Military City, Riyadh, disease with a very poor prognosis. Better understanding of the complex pathobiology of PAH has led to a Saudi Arabia, major therapeutic evolution. International regulatory agencies have approved many specific drugs with different 1Pulmonary Medicine, pharmacologic pathways and routes of administration. In the year 2013, two new drugs with great potentials Vancouver General in managing PAH have been added to the treatment options, macitentan and riociguat. Additional drugs are expected to come in the near future. Hospital, Vancouver, BC, Canada, A substantial body of evidence has confirmed the effectiveness ofpulmonary arterial hypertension (PAH)-specific therapies in improving the patients’ symptomatic status and slowing down the rate of clinical deterioration. 2Department of Organs Transplant, 3Pulmonary Although the newer modern medications have significantly improved the survival of patients with PAH,it remains a Medicine, King Faisal non-curable and fatal disease. Lung transplantation (LT) remains the only therapeutic option for selected patients with advanced disease who continue to deteriorate despite optimal therapy. Specialist Hospital & Research Center, Key words: Riyadh, Saudi Arabia Specific therapy, target therapy, pulmonary arterial hypertension, lung transplant, Saudi association for pulmonary hypertension guidelines Address for correspondence: Dr. Majdy M Idrees, MD uring the last decade, there have Severity in the main guidelines), the vasoreactive Pulmonary Medicine, been enormous improvements in our response, and access to specific treatment.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
  • Study Protocol

    Study Protocol

    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).